OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC.

Abstract

SABR is a locally effective modality for metastatic renal cell carcinoma (RCC) (1, 2). Preclinical data in RCC has demonstrated improved disease control in both irradiated and unirradiated sites with single fraction SABR and anti-PD1 checkpoint blockade (3), although prospective clinical trials with this combination have not yet been reported. RAPPORT is a multi-institutional, single arm, phase 1b/II clinical trial (NCT02855203). Patients with 1-5 oligometastases from clear cell RCC were eligible. They received a single fraction SABR of 18-20Gy to all metastases (or 30Gy in 10 fractions of conventional radiotherapy if SABR was not feasible) followed by 8 x 3 weekly cycles of 200mg intravenous pembrolizumab. This is a preplanned interim safety analysis of the first 12 patients who completed SABR and 12 weeks of pembrolizumab. Adverse events were graded using CTCAE v4.0.